Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis
Relapsing polychondritis (RPC) is an autoimmune disease characterized by the inflammation of cartilaginous tissues and other proteoglycan rich tissues. A concomitant disease, particularly myelodysplasia or systemic autoimmune disease can be detected in one-third of the patients with RPC. Unlike adul...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2018-07-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/1214 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689170350440448 |
|---|---|
| author | E. G. Khaleva G. A. Novik F. V. Rokhlina |
| author_facet | E. G. Khaleva G. A. Novik F. V. Rokhlina |
| author_sort | E. G. Khaleva |
| collection | DOAJ |
| description | Relapsing polychondritis (RPC) is an autoimmune disease characterized by the inflammation of cartilaginous tissues and other proteoglycan rich tissues. A concomitant disease, particularly myelodysplasia or systemic autoimmune disease can be detected in one-third of the patients with RPC. Unlike adults in children, RPC is less often associated with other autoimmune diseases. The diagnosis of RPC is established using the criteria of Mc Adam (1976) or Damiani (1979). The basis of the pathogenesis of RPC is an autoimmune reaction, which is initially directed against cartilage and then spreads to non-cartilaginous tissues. One of the elements in the pathogenesis of RPC is the mechanical trauma of cartilage, resulting in the release of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon-γ, interleukin-8, and macrophage inflammatory protein 1) and local inflammation followed by the formation of autoantibodies in a patient with a genetic predisposition. In the treatment of RPC, steroids, non-steroidal anti-inflammatory drugs, colchicine are used and, if they are ineffective, immunosuppressants are prescribed. The most effective anti-cytokine drugs used in the treatment of RPC are tumor necrosis factor-alpha (TNF-α) inhibitors, IL-1 receptor antagonists, an inhibitor of the costimulatory pathway of T-lymphocyte activation, monoclonal antibodies against the IL-6 receptor. Given the fact that management of these patients is very complex, the aim of the study is to review available data on pathogenetic mechanisms of biological agents in managing of relapsing polychondritis. |
| format | Article |
| id | doaj-art-43ecff4332ea42708973ed6c9d1c4606 |
| institution | DOAJ |
| issn | 1682-0363 1819-3684 |
| language | English |
| publishDate | 2018-07-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj-art-43ecff4332ea42708973ed6c9d1c46062025-08-20T03:21:43ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842018-07-0117216717410.20538/1682-0363-2018-2-167-174800Pathogenetic mechanisms of biological agents in managing of relapsing polychondritisE. G. Khaleva0G. A. Novik1F. V. Rokhlina2Saint-Petersburg State Pediatric Medical UniversitySaint-Petersburg State Pediatric Medical UniversitySaint-Petersburg State Pediatric Medical University Research Сhildren’s Orthopedic Institute named after G.I. TurnerRelapsing polychondritis (RPC) is an autoimmune disease characterized by the inflammation of cartilaginous tissues and other proteoglycan rich tissues. A concomitant disease, particularly myelodysplasia or systemic autoimmune disease can be detected in one-third of the patients with RPC. Unlike adults in children, RPC is less often associated with other autoimmune diseases. The diagnosis of RPC is established using the criteria of Mc Adam (1976) or Damiani (1979). The basis of the pathogenesis of RPC is an autoimmune reaction, which is initially directed against cartilage and then spreads to non-cartilaginous tissues. One of the elements in the pathogenesis of RPC is the mechanical trauma of cartilage, resulting in the release of pro-inflammatory cytokines (tumor necrosis factor alpha, interferon-γ, interleukin-8, and macrophage inflammatory protein 1) and local inflammation followed by the formation of autoantibodies in a patient with a genetic predisposition. In the treatment of RPC, steroids, non-steroidal anti-inflammatory drugs, colchicine are used and, if they are ineffective, immunosuppressants are prescribed. The most effective anti-cytokine drugs used in the treatment of RPC are tumor necrosis factor-alpha (TNF-α) inhibitors, IL-1 receptor antagonists, an inhibitor of the costimulatory pathway of T-lymphocyte activation, monoclonal antibodies against the IL-6 receptor. Given the fact that management of these patients is very complex, the aim of the study is to review available data on pathogenetic mechanisms of biological agents in managing of relapsing polychondritis.https://bulletin.ssmu.ru/jour/article/view/1214relapsing polychondritisclinicsetiopathogenesisbiological agents |
| spellingShingle | E. G. Khaleva G. A. Novik F. V. Rokhlina Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis Бюллетень сибирской медицины relapsing polychondritis clinics etiopathogenesis biological agents |
| title | Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| title_full | Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| title_fullStr | Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| title_full_unstemmed | Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| title_short | Pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| title_sort | pathogenetic mechanisms of biological agents in managing of relapsing polychondritis |
| topic | relapsing polychondritis clinics etiopathogenesis biological agents |
| url | https://bulletin.ssmu.ru/jour/article/view/1214 |
| work_keys_str_mv | AT egkhaleva pathogeneticmechanismsofbiologicalagentsinmanagingofrelapsingpolychondritis AT ganovik pathogeneticmechanismsofbiologicalagentsinmanagingofrelapsingpolychondritis AT fvrokhlina pathogeneticmechanismsofbiologicalagentsinmanagingofrelapsingpolychondritis |